Biodefense refers to the methods of restoring biosecurity in the body that is or can be exposed to biological threats or contagious illnesses that can possibly spread all around the world. Its scope also includes the detection and prevention of biological attacks.
It is believed the United States government has allocated an undetermined amount from the national fund gathered from taxpayers for various biodefense projects. However, arguably these funds are not enough to sustain and maintain many of the biodefense projects in the works. If they were continued, these projects would have been the protection people would need in defending bioterrorism—a layer of defense against the hazards of biological agents containing highly contagious diseases. For billionaire and philanthropist Bill Gates, he warns no one is ready, and the lack of biodefense is worrisome.
In one of the panels at the Munich Security Conference conducted February 17–19, 2017, the Microsoft co-founder spoke and admonished global leaders about the next global epidemic having a strong chance of coming from a computer screen.
Gates’ worries echoed those of biodefense companies. Leaders and investors are urged to invest and support biodefense companies by allocating more funds and biodefense stocks, respectively. It’s not just about profit: helping develop the necessary products to combat the biological threats may just save lives in the near future. Take a look at these three biosecurity companies that can change the biodefense game:
PharmAthene, Inc. (NYSEMKT:PIP)
PharmAthene, a company that develops “medical countermeasures against biological and chemical risks,” is creating a next-generation anthrax vaccine. Despite its shares rating being downgraded by TheStreet, Community Financial News reports that the company is optimistic about its stocks growing in short interest. This is due to the anthrax vaccine becoming a necessity amid bioterrorism threats and the possibility of a global pandemic just on the horizon.
Northrop Grumman Corporation (NYSE:NOC)
Meanwhile, InvestorPlace notes that Northrop Grumman Corporation is currently enjoying its high stock price. In biodefense, the company seeks to provide more solutions for the enhancement of the national medical research. Northrop Grumman also aims to give advanced bioinformatics and system integration leadership and support to the global health community.
With biodefense stocks on the rise, it seems that not only is the biodefense industry making a comeback, it is also on its way to fortifying defenses and finding more measures and methods against bioterrorism attacks.
Could the Coronavirus finally burst the debt bubble?
Nothing seems to be getting in the way of the melt-up. Not even coronavirus has knocked it off its upward...
Gold continues its bull market advance
The Dow Jones is continuing its upward trend, making a new all-time high on Wednesday. Since the end of September...
Hepatitis C drugs save Spain $681 million
Hepatitis C is a contagious viral liver disease and has become the most common blood-borne disease in the U.S., with...
The number of direct electricity consumers triples in two years
Direct consumers to the electricity market have tripled their influence in the last two years and now represent 2.5% of...
Crowdfunding in Italy raises more than $178 million in 2019
Crowdfunding has been a growth market the world over. Italy saw a crowdfunding boom in 2019, raising a record $178...
- Featured4 days ago
La perturbation numérique prend l’assaut du département de la Dordogne
- Featured7 days ago
What is in store for the Brazil fintech sector in 2020?
- Business6 days ago
Rural incubator, UNIQORN, takes on World Business Angels Investment Forum in Istanbul
- Business6 days ago
America’s ban on Chinese drones has created an enormous opportunity for investors